ASH 2020 | Discordances between immunofixation vs NGF vs NGS in myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the investigation into why minimal residual disease (MRD) assessments in patients with multiple myeloma patients can be inconsistent with immunofixation assessments. Using next-generation flow (NGF) and sequencing (NGS) techniques, it was found that 11% of patients with a negative MRD assessment through NGF continued to show positive immunofixation. Immature cells carrying the clonotypic B-cell receptor immunoglobulin (BcR IG) cannot drive relapse but could be the source of inconsistent results between NGF and NGS. The results suggest secondary driver mutations or copy number alterations may follow mutated and clonally expanded lymphopoiesis, leading to the growth of multiple myeloma plasma cells. This interview took place during the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
